ArticleJournal of veterinary internal medicine
Use of thymidine kinase 1 autoantibody, thymidine kinase antigen, extracellular protein kinase A autoantibody, and C-reactive protein for early detection of malignant tumors in dogs.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Use of thymidine kinase 1 autoantibody, thymidine kinase antigen, extracellular protein kinase A autoantibody, and C-reactive protein for early detection of malignant tumors in dogs.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundAlthough the importance of early diagnosis of malignant tumors is a major concern, an easily accessible in-house method has not been established.
objectivesTo investigate the most optimal model by combining thymidine kinase 1 (TK1) autoantibody, extracellular protein kinase A (ECPKA) autoantibody, TK1 antigen, C-reactive protein (CRP), age, breed, and sex. ANIMALS: Serum samples from 1702 dogs were collected from local animal hospitals and referral animal medical centers in Korea.
methodsTK1 autoantibody, ECPKA autoantibody, and CRP were measured using LFIA methods in serum samples of dog to design a new neoplastic index (NI) for early detection of malignant tumors in dogs.
resultsAUC of TK1 autoantibody model with TK1 antigen, CRP, age, and breed in multiple logistic regression analysis was 0.966 (TK1 autoantibody, P = .0005; TK1 antigen, P = .0003), and when the cutoff value was 0.417, the specificity was 87.1%, and sensitivity was 96.4%. Regression coefficients were 24.4, 20.5, 24.8, 10.6, respectively in TK1 autoantibody, TK1 antigen, CRP, and age, and the effect by breed (regression coefficient 2.1, 3.0) was the lowest. The same multiple logistic regression analysis on dogs with lymphoma, and AUC of TK1 autoantibody model was 0.981 (all P < .0001, TK1 antigen P = .09), when the cutoff value was 0.352, the specificity was 92.9%, and sensitivity was 93.7%. CONCLUSIONS AND CLINICAL IMPORTANCE: The NI including TK1 autoantibody could be useful in the screening test for both lymphoma and other tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.